惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

阮一峰的网络日志
阮一峰的网络日志
博客园 - 司徒正美
D
DataBreaches.Net
宝玉的分享
宝玉的分享
奇客Solidot–传递最新科技情报
奇客Solidot–传递最新科技情报
博客园 - 【当耐特】
人人都是产品经理
人人都是产品经理
博客园 - Franky
让小产品的独立变现更简单 - ezindie.com
让小产品的独立变现更简单 - ezindie.com
IT之家
IT之家
博客园 - 三生石上(FineUI控件)
J
Java Code Geeks
腾讯CDC
博客园_首页
The Cloudflare Blog
S
SegmentFault 最新的问题
C
Check Point Blog
美团技术团队
爱范儿
爱范儿
大猫的无限游戏
大猫的无限游戏
Hugging Face - Blog
Hugging Face - Blog
T
The Blog of Author Tim Ferriss
A
About on SuperTechFans
Blog — PlanetScale
Blog — PlanetScale

Latest Business Laws, Legal Insights, News & Updates | The HinduBusinessLine

Corporations have a fundamental duty to protect ecosystem: SC holds How to copyright colours Only strong reforms can clear massive backlog of court cases SC reasserts ‘bail is the rule’ doctrine in landmark ruling Misleading ads: How global brands are testing India’s regulatory framework How the Supreme Court verdict is set to reshape India’s mining industry Income Tax tribunal paves way for double deduction claims Where does the liability of the principal borrower begin and end? Why fixed-dose combination drugs need a tighter leash Who is a ‘workman’? SC reiterates binding nature of government tenders Corporate guarantee: A ‘yearly’ quandary A treaty to protect traditional knowledge IBBI’s proposed ‘guarantees’ under fire Guidelines diminish arbitration’s role in government procurement disputes Tooth-and-nail fight over trademark colours RBI expands overseas portfolio investment options Balancing business revival and creditor interests under IBC: A statistical insight Upholding tenets of fairness in arbitration ‘Conscious acceptance’ necessary for arbitration agreements AI under new management: EU sets global standard with Artificial Intelligence Act DMRC vs DAMEPL: A legal rollercoaster culminates as SC presents ‘cure’ Indian innovators rally behind Digital Competition Bill New CCI regulations: Tightening the reins on confidential information Amending nuclear law to spur ‘pink’ hydrogen generation Level up or Log out: India’s gaming industry at a crossroads Blurred boundaries: Taxing escrowed funds in M&A deals No consideration, no tax When insolvency meets money laundering Strengthening whistleblowers’ hands
Trademark issues in naming drugs
By Team Gavel · 2023-12-31 · via Latest Business Laws, Legal Insights, News & Updates | The HinduBusinessLine

Do IMOX and INIMOX sound so similar to you that you will be confused over which to ask for when you stand at the pharmacy counter?

IMOX is a brand that belongs to IPCA Laboratories Pvt Ltd; INIMOX is of Indian Immunologicals Ltd. IPCA objected (successfully) to INIMOX to the Registrar of Trade Marks Registry. A legal dispute ensued, which was settled by the Madras High Court last month.

The Court ruled in favor of Indian Immunologicals Ltd, noting that there were key differences between the two drugs. IMOX is a tablet for humans; INIMOX an injection for animals. Case closed.

Indian Immunologicals Ltd offered several legal precedents of similar-sounding names where no relief was granted to the objecting party. Some of them are: Stimuliv (Corona Remedies) and Stimu-let (Franco-Indian Pharmaceuticals), Meto (Orchid Chemicals) and Metox (Wockhardt), Zincovit (Apex Laboratories) and Zinconia (Zuventus Health Care), Meronem (Astrazeneca) and Meromer (Orchid Chemicals), Netromycin (Schering Corporation) and Netmicin (United Biotech).

However, there is a larger issue underlying the dispute. The names of most of the drugs sold in the market are derived from their underlying ‘active pharmaceutical ingredient’. Therefore, when rival companies name their drugs, the names are bound to be somewhat similar. How do you register their names?

The Madras High Court judgment lays down certain principles, which have been analysed by Vindhya Mani, Mohit Kar and Kriti Sood, lawyers at the law firm Lakshmikumaran & Sridharan, in an article in Mondaq. They note: “The Court concluded that marks that are derived from API or generic names are weaker in comparison to arbitrary or coined marks. The Court held that the larger the portion of the API or disease name that a mark uses, the weaker is its protection. Similarly, if a mark contains additional terms and unique elements apart from what it has borrowed from an API or disease name, then its protection would be stronger. This apart, the Court maintained that the analysis of “visual, phonetic and structural” similarity will play an important role in deciding the outcome of infringement, passing off, or proceedings involving strength of marks.”

Published on December 31, 2023